SEC 13F Intelligence

Enavate Sciences GP, LLC / BBOT

Enavate Sciences GP, LLC’s Bridgebio Oncology Therapeut Position

Does Enavate Sciences GP, LLC own Bridgebio Oncology Therapeut (BBOT)? Yes2.63M shares worth $24M (+6.69% of its 13F portfolio) as of Q1 2026.

Position Value
$24M
Q1 2026
Shares
2.63M
% of Portfolio
+6.69%
Quarters Held
3
currently held

Position History BBOT

Reported value by quarter
Q3 ’25: $30MQ3 ’25Q4 ’25: $33MQ4 ’25Q1 ’26: $24MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 20262.63M$24M+6.69%
Q4 20252.63M$33M+6.49%
Q3 20252.63M$30M+9.29%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Enavate Sciences GP, LLC’s full portfolio or all institutional holders of BBOT.